Seeger Weiss Represents Henrietta Lacks Family in New Lawsuit Against Novartis and Viatris

On August 5, 2024, the family of Henrietta Lacks, represented by Seeger Weiss partners Chris Seeger and Chris Ayers, alongside nationally renowned civil rights attorney Ben Crump, filed a lawsuit against Novartis Pharmaceuticals Corporation and Novartis Gene Therapies Inc. (“Novartis”), as well as Viatris Inc. and its subsidiary Mylan Pharmaceuticals, in the United States District […]

August 6, 2024

On August 5, 2024, the family of Henrietta Lacks, represented by Seeger Weiss partners Chris Seeger and Chris Ayers, alongside nationally renowned civil rights attorney Ben Crump, filed a lawsuit against Novartis Pharmaceuticals Corporation and Novartis Gene Therapies Inc. (“Novartis”), as well as Viatris Inc. and its subsidiary Mylan Pharmaceuticals, in the United States District Court for the District of Maryland.

In 1951, Henrietta Lacks was diagnosed with cervical cancer in a racially segregated ward at Johns Hopkins Hospital. During her treatment, tissue samples were surgically extracted from her body without her knowledge or consent. These stolen cells were cultivated into the first immortal cell line, known as HeLa cells, which have been instrumental in numerous pioneering medical discoveries, from the gene mapping to in vitro fertilization and the COVID-19 vaccine.

Novartis and Viatris are among the corporations that have profited from her cells, while Mrs. Lacks and her family have never received any compensation. Both companies continue to exploit her cells without permission or consent from the Lacks family.

“The world now knows the story of Henrietta Lacks, which makes it all the more shocking, though not surprising, that pharmaceutical giants Novartis and Viatris continue to profit off the deeply unethical origins of HeLa cells and the disturbing history of medical racism,” said Chris Seeger. “Representing the Lacks family and preserving Mrs. Lacks’s legacy is one of the greatest honors of my career. We pledge to hold these companies accountable for exploiting her stolen cells.”

This lawsuit filing follows a pivotal ruling in May, when a federal court allowed the Lacks family to proceed with their lawsuit against Ultragenyx Pharmaceutical Inc., another company that profited from Mrs. Lacks’ cells without her knowledge or consent.

Related News

July 28, 2026
Seeger Weiss Named Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards

Seeger Weiss has been named as Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards. This honor is reflects to the Seeger Weiss team’s efforts throughout the entire Pharmaceutical Litigation practice area, but specifically the firm’s work on the GLP-1 RA and Depo-Provera litigations. Partner Parvin Aminolroaya […]

Read More
July 28, 2026
Plaintiffs Reach Uncapped Global Settlement With J&J, Company to Pay Minimum of $5.8 Billion to Resolve Talc Litigation After More Than a Decade

The Plaintiffs’ Negotiation Committee in multi-district litigation 2738 (District of New Jersey), with the support and endorsement of the Plaintiffs’ Executive Committee and the Plaintiffs’ Steering Committee, announces today that it has reached a historic uncapped global settlement with J&J, Company to pay a minimum $5.8 billion settlement to resolve all current and pending talcum […]

Read More
June 29, 2026
Seeger Weiss Earns Tier 1 Ranking in the 2026 Legal 500 USA Guide

Seeger Weiss is proud to announce that the firm has been selected for a Tier 1 ranking in the 2026 Legal 500 USA Guide in the Product Liability, Mass Tort and Class Action: Plaintiff category. Founding Partner Christopher Seeger was selected for inclusion in the category’s Hall of Fame in recognition of his continued leadership […]

Read More